JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first

Andrew Obenshain officially took over as bluebird bio’s CEO when the company split into two back in November. But there’s one item from his prior desk that's still on his mind: the removal of Zynteglo from the European market.